Devjit Tripathy1,2, Aurora Merovci1, Rita Basu3, Muhammad Abdul-Ghani1, Ralph A DeFronzo1,2. 1. Department of Medicine, Diabetes Division, University of Texas Health Science, San Antonio, Texas. 2. Audie L Murphy Veterans Affairs Hospital, South Texas Veterans Heath Care System, San Antonio, Texas. 3. Department of Medicine, Endocrinology Division, University of Virginia School of Medicine, Charlottesville, Virginia.
Abstract
CONTEXT: Chronic hyperglycemia worsens skeletal muscle insulin resistance and β-cell function. However, the effect of sustained physiologic hyperglycemia on hepatic insulin sensitivity is not clear. OBJECTIVE: To examine the effect of sustained physiologic hyperglycemia (similar to that observed in patients with type 2 diabetes) on endogenous (primarily reflecting hepatic) glucose production (EGP) in healthy individuals. DESIGN: Volunteers participated in a three-step hyperinsulinemic (10, 20, 40 mU/m2 per minute) euglycemic clamp before and after a 48-hour glucose infusion to increase plasma glucose concentration by ∼40 mg/dL above baseline. EGP was measured with 3-3H-glucose before and after chronic glucose infusion. PARTICIPANTS: Sixteen persons with normal glucose tolerance [eight with and eight without a family history (FH) of diabetes] participated in the study. MAIN OUTCOME MEASURE: EGP. RESULTS: Basal EGP increased following 48 hours of glucose infusion (from a mean ± SEM of 2.04 ± 0.08 to 3.06 ± 0.29 mg/kgffm⋅ min; P < 0.005). The hepatic insulin resistance index (basal EGP × fasting plasma insulin) markedly increased following glucose infusion (20.1 ± 1.8 to 51.7 ± 6.6; P < 0.005) in both FH+ and FH- subjects. CONCLUSION: Sustained physiologic hyperglycemia for as little as 48 hours increased the rate of basal hepatic glucose production and induced hepatic insulin resistance in health persons with normal glucose tolerance, providing evidence for the role of glucotoxicity in the increase in hepatic glucose production in type 2 diabetes.
CONTEXT: Chronic hyperglycemia worsens skeletal muscle insulin resistance and β-cell function. However, the effect of sustained physiologic hyperglycemia on hepatic insulin sensitivity is not clear. OBJECTIVE: To examine the effect of sustained physiologic hyperglycemia (similar to that observed in patients with type 2 diabetes) on endogenous (primarily reflecting hepatic) glucose production (EGP) in healthy individuals. DESIGN: Volunteers participated in a three-step hyperinsulinemic (10, 20, 40 mU/m2 per minute) euglycemic clamp before and after a 48-hour glucose infusion to increase plasma glucose concentration by ∼40 mg/dL above baseline. EGP was measured with 3-3H-glucose before and after chronic glucose infusion. PARTICIPANTS: Sixteen persons with normal glucose tolerance [eight with and eight without a family history (FH) of diabetes] participated in the study. MAIN OUTCOME MEASURE: EGP. RESULTS: Basal EGP increased following 48 hours of glucose infusion (from a mean ± SEM of 2.04 ± 0.08 to 3.06 ± 0.29 mg/kgffm⋅ min; P < 0.005). The hepatic insulin resistance index (basal EGP × fasting plasma insulin) markedly increased following glucose infusion (20.1 ± 1.8 to 51.7 ± 6.6; P < 0.005) in both FH+ and FH- subjects. CONCLUSION: Sustained physiologic hyperglycemia for as little as 48 hours increased the rate of basal hepatic glucose production and induced hepatic insulin resistance in health persons with normal glucose tolerance, providing evidence for the role of glucotoxicity in the increase in hepatic glucose production in type 2 diabetes.
Authors: Guenther Boden; Peter Cheung; T Peter Stein; Karen Kresge; Maria Mozzoli Journal: Am J Physiol Endocrinol Metab Date: 2002-07 Impact factor: 4.310
Authors: A Gastaldelli; E Toschi; M Pettiti; S Frascerra; A Quiñones-Galvan; A M Sironi; A Natali; E Ferrannini Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: G Veerababu; J Tang; R T Hoffman; M C Daniels; L F Hebert; E D Crook; R C Cooksey; D A McClain Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: Aron Adkins; Rita Basu; Mai Persson; Betty Dicke; Pankaj Shah; Adrian Vella; W Frederick Schwenk; Robert Rizza Journal: Diabetes Date: 2003-09 Impact factor: 9.461
Authors: Christopher E Shannon; Aurora Merovci; Marcel Fourcaudot; Devjit Tripathy; Muhammad Abdul-Ghani; Hu Wang; Xianlin Han; Luke Norton; Ralph A DeFronzo Journal: J Clin Endocrinol Metab Date: 2022-07-14 Impact factor: 6.134
Authors: Sine W Jørgensen; Line Hjort; Linn Gillberg; Louise Justesen; Sten Madsbad; Charlotte Brøns; Allan A Vaag Journal: Am J Physiol Endocrinol Metab Date: 2020-12-07 Impact factor: 4.310
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23
Authors: Clarice Cavalero Nebuloni; Roberta de Oliveira Máximo; Cesar de Oliveira; Tiago da Silva Alexandre Journal: J Gerontol A Biol Sci Med Sci Date: 2020-05-22 Impact factor: 6.053